

Stanford



Paul Kwo

Professor of Medicine (Gastroenterology and Hepatology)
Medicine - Gastroenterology & Hepatology

CLINICAL OFFICE (PRIMARY)

- **Gastroenterology and Hepatology: Administrative Office**

430 Broadway St
Pavilion C 3rd Floor
Redwood City, CA 94063
Tel (650) 736-5555 Fax (650) 498-6323

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Lorraine Ibana - Administrative Associate
Email libana12@stanford.edu
Tel 650-723-5135

Bio

BIO

Dr. Kwo is currently Professor of Medicine and Director of Hepatology at the Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He has distinguished himself in the field of Hepatitis C therapeutics and has been the principal investigator on multiple international trials. He recently authored the ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

CLINICAL FOCUS

- Hepatology
- Liver Transplant
- Gastroenterology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Gastroenterology & Hepatology

ADMINISTRATIVE APPOINTMENTS

- Liver Clinic Chief, Digestive Health, (2018- present)
- Director of Hepatology, Stanford University, (2016- present)

HONORS AND AWARDS

- Best Doctors Gastroenterology/Hepatology, Best Doctors in America (2003-2015)
- Outstanding Young Clinician, Department of Medicine, Indiana University School of Medicine (2003)
- America's Top Doctors Gastroenterology/Hepatology, Consumers Research Council of America (2002-2014)
- America's Best Doctors: Gastroenterology/Hepatology, Best Doctors in America (2003-2015)
- America's Top Doctors, Gastroenterology/Hepatology, Castle Connelly Publishing, (2002-2016, 2018-2020)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Development Committee, American Association for the Study of Liver Diseases (2015 - present)
- Editorial Board, Journal of Clinical Gastroenterology (2013 - present)
- Nominating Committee, American Association for the Study of Liver Disease (2016 - present)
- Board of Trustees, American College of Gastroenterology (2015 - present)

PROFESSIONAL EDUCATION

- Residency: University of Maryland Medical Center (1991) MD
- Board Certification: Transplant Hepatology, American Board of Internal Medicine (2006)
- Board Certification: Gastroenterology, American Board of Internal Medicine (1995)
- Fellowship: Mayo Clinic Graduate Medical Education (1995) MN
- Medical Education: Wayne State University School of Medicine (1988) MI

LINKS

- Division Of Gastroenterology & Hepatology: <http://www.gastrohep.stanford.edu>

Research & Scholarship

CLINICAL TRIALS

- A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD), Recruiting
- A Longitudinal Observational Study of the Natural History and Management of Patients With HCC, Recruiting
- A Study of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus, Not Recruiting
- ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement, Not Recruiting
- Direct Acting Antiviral-Post Authorization Safety Study, Not Recruiting
- Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT), Not Recruiting
- Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH), Not Recruiting
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a, Not Recruiting

Teaching

COURSES

2024-25

- Science of Medicine II-A: INDE 222A (Aut)

2023-24

- Science of Medicine II-A: INDE 222A (Aut)

2022-23

- Science of Medicine II-A: INDE 222A (Aut)

2021-22

- Science of Medicine II-A: INDE 222A (Aut)

Publications

PUBLICATIONS

- **Alcohol Use in Liver Transplant Recipients With Alcohol-related Liver Disease: A Comparative Assessment of Relapse Prediction Models.** *Transplantation*
Sedki, M., Kwong, A., Bhargava, M., Ahmed, A., Daugherty, T., Kwo, P., Dronamraju, D., Kumari, R., Kim, W. R., Esquivel, C., Melcher, M., Bonham, C. A., Gallo, et al
2023
- **Epidemiology and Disease Burden of Alcohol Associated Liver Disease.** *Journal of clinical and experimental hepatology*
Aslam, A., Kwo, P. Y.
2023; 13 (1): 88-102
- **Hepatitis C Screening in Post-Baby Boomer Generation Americans: One Size Does Not Fit All.** *Mayo Clinic proceedings*
Sripongpun, P., Udompap, P., Mannalithara, A., Downing, N. L., Vidovszky, A. A., Kwong, A. J., Goel, A., Kwo, P. Y., Kim, W. R.
2023; 98 (9): 1335-1344
- **Viral Hepatitis and Acute-on-Chronic Liver Failure.** *Clinics in liver disease*
Bhatti, T. K., Singal, A. K., Kwo, P. Y.
2023; 27 (3): 617-630
- **Use and outcomes of hepatitis B virus positive grafts for renal or heart transplantation in the US (1999-2021)**
Singal, A., Reddy, K., Mindie Nguyen, Younossi, Z. M., Kwo, P., Kuo, Y.
ELSEVIER.2023: S468
- **Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study**
Clark, V., Strange, C., Strnad, P., Sanchez, A., Kwo, P., Pereira, V., Van Hoek, B., Barjaktarevic, I., Corsico, A., Pons, M., Goldklang, M., Gray, M., Kuhn, et al
ELSEVIER.2023: S90-S91
- **Accuracy of Information Provided by ChatGPT Regarding Liver Cancer Surveillance and Diagnosis.** *AJR. American journal of roentgenology*
Cao, J. J., Kwon, D. H., Ghaziani, T. T., Kwo, P., Tse, G., Kesselman, A., Kamaya, A., Tse, J. R.
2023
- **Clinical trials reimaged.** *Hepatology (Baltimore, Md.)*
Kwo, P. Y., Patel, T.
2023
- **Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis.** *ACG case reports journal*
Achal, S., Berry, R., Wei, M. T., Banerjee, S., Ghanouni, P., Kambham, N., Kwo, P. Y.
2023; 10 (4): e01044
- **Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications.** *Journal of clinical and translational hepatology*
Kuo, Y. F., Kwo, P., Wong, R. J., Singal, A. K.
2023; 11 (1): 130-135
- **Portopulmonary Hypertension.** *Clinics in liver disease*
Lai, Y. K., Kwo, P. Y.
2023; 27 (1): 71-84
- **Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know.** *The American journal of gastroenterology*
Wong, F., Kwo, P.
2023
- **Final results from the ribavirin pregnancy registry, 2004-2020.** *Birth defects research*

- Sinclair, S. M., Jones, J. K., Miller, R. K., Greene, M. F., Kwo, P. Y., Maddrey, W. C.
2022
- **Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US.** *Alimentary pharmacology & therapeutics*
Singal, A. K., Kuo, Y., Reddy, K. R., Bataller, R., Kwo, P.
2022
 - **CHARACTERISTICS AND CARE OF CHRONIC HEPATITIS B PATIENTS WITH ADVANCED PRACTICE PROVIDERS**
Kam, L., Huang, D., Tobias, A. F., Poon, K., Henry, L., Kwo, P., Cheung, R., Nguyen, M. H.
WILEY.2022: S279-S280
 - **THE IMPACT OF TELEHEALTH USAGE ON LIVER TRANSPLANT EVALUATIONS DURING COVID-19**
Jowell, A., Kwong, A. J., Daugherty, T., Kwo, P.
WILEY.2022: S1057-S1058
 - **A NOVEL EDUCATIONAL PROGRAM TO ADDRESS MISUNDERSTANDINGS IN APPLYING AASLD HBV TREATMENT GUIDELINES**
Ahn, J., Anderson, S., Dela Cruz, A., Kwo, P., Nguyen, M. H., Schwartz, Z.
WILEY.2022: S296-S297
 - **Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.** *BMC gastroenterology*
Alshuwaykh, O., Cheung, A., Goel, A., Kwong, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Nguyen, M., Kim, W. R., Kwo, et al
2022; 22 (1): 410
 - **Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.** *Hepatology communications*
Alshuwaykh, O., Daugherty, T., Cheung, A., Goel, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Dronamraju, D., Kumari, R., Kwong, A., Nguyen, M., Kim, W. R., Kwo, et al
2022
 - **Utilization and outcomes of hepatitis B-positive grafts in orthotopic liver transplantation in the United States, 1999-2021.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Ali, S. E., Vutien, P., Bonham, C. A., Landis, C., Kwo, P., Esquivel, C., Nguyen, M. H.
2022
 - **Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naive patients with HBeAg positive chronic hepatitis B**
Sulkowski, M. S., Fung, S. K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H. L., Dieterich, D. T., Nahass, R. G., Park, J. S., Chan, S., Han, S. B., Gane, E. J., Bennett, et al
ELSEVIER.2022: S836-S837
 - **Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.** *Journal of hepatology*
Sulkowski, M. S., Agarwal, K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H. L., Dieterich, D. T., Nahass, R. G., Park, J. S., Chan, S., Han, S. B., Gane, E. J., Bennett, et al
2022
 - **Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization.** *Clinical transplantation*
Singal, A. K., Kuo, Y., Kwo, P., Mahmud, N., Sharma, P., Nadim, M. K.
2022: e14700
 - **First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir adefenamide.** *Hepatology communications*
Pan, C. Q., Afdhal, N. H., Ankoma-Sey, V., Bae, H., Curry, M. P., Dieterich, D., Frazier, L., Frick, A., Hann, H., Kim, W. R., Kwo, P., Milligan, S., Tong, et al
2022
 - **Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.** *Journal of hepatology*
Yuen, M. F., Agarwal, K., Ma, X., Nguyen, T. T., Schiff, E. R., Hann, H. L., Dieterich, D. T., Nahass, R. G., Park, J. S., Chan, S., Han, S. B., Gane, E. J., Bennett, et al

2022

- **Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer.** *Alcoholism, clinical and experimental research*
Singal, A. K., Kwo, P.
2022
- **Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.** *Journal of general internal medicine*
Halket, D., Dang, J., Phadke, A., Jayasekera, C., Kim, W. R., Kwo, P., Downing, L., Goel, A.
2022
- **Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.** *Hepatology (Baltimore, Md.)*
Pan, C. Q., Jacobson, I. M., Martin, P., Kwo, P., Lim, J., Han, S. B., Hu, K., Ahn, J., Tong, M. J.
1800
- **THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS WITH CIRRHOSIS NOT MEETING CURRENT TREATMENT GUIDANCE**
Alshuwaykh, O., Goel, A., Ghaziani, T., Daugherty, T., Dhanasekaran, R., Ahmed, A., Dronamraju, D., Kwong, A. J., Nguyen, M. H., Cheung, A., Kwo, P.
WILEY.2021: 500A-501A
- **IMPACT OF NEW SIMULTANEOUS LIVER KIDNEY ALLOCATION POLICY ON POST LIVER TRANSPLANT OUTCOMES AND NUMBER OF KIDNEYS USED**
Waleed, M., Maan, M., Kuo, Y., Kwo, P., Mahmud, N., Sharma, P., Nadim, M. K., Singal, A. K.
WILEY.2021: 849A-850A
- **HBV PGRNA AND DNA BOTH REBOUND IMMEDIATELY FOLLOWING DISCONTINUATION OF THE CORE INHIBITOR VEBICORVIR DESPITE CONTINUED NRTI TREATMENT IN PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION: FINDINGS FROM A PHASE 2 OPEN LABEL STUDY**
Yuen, M., Ma, X., Hassanein, T. I., Kwo, P., Ma, J., Li, L., Kitrinis, K., Knox, S. J., Stamm, L. M., Bae, H., Sulkowski, M. S., Elkhatab, M., Agarwal, et al
WILEY.2021: 65A-66A
- **PREDICTORS OF ELEVATED LIVER TESTS DURING COVID-19 SHELTER IN PLACE IN CHRONIC LIVER DISEASE PATIENTS**
Alshuwaykh, O., Wong, R. J., Kim, W., Torok, N. J., Jiang, J., Kwo, P.
WILEY.2021: 334A
- **STANFORD INTEGRATED PSYCHOSOCIAL ASSESSMENT FOR TRANSPLANT (SIPAT) IS SUPERIOR TO SALT AND HRAR IN IDENTIFYING LT CANDIDATES WITH ALD AT LOW RISK OF RELAPSE**
Sedki, M., Kwo, P., Ahmed, A., Hussain, F., Kwong, A. J., Goel, A.
WILEY.2021: 253A-254A
- **PSYCHOSOCIAL PREDICTORS OF ALCOHOL RELAPSE AMONG LIVER TRANSPLANT CANDIDATES WITH ALCOHOL-RELATED LIVER DISEASE**
Sedki, M., Kwo, P., Ahmed, A., Hussain, F., Kwong, A. J., Goel, A.
WILEY.2021: 246A-247A
- **Alcoholic Hepatitis and its Many Facets.** *Clinics in liver disease*
Kwo, P. Y.
2021; 25 (3): xiii-xiv
- **Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection.**
Gane, E., Sulkowski, M., Ma, X., Nguyen, T., Hann, H., Hassanein, T., Elkhatab, M., Chan, S., Nahass, R., Bennett, M., Park, J., Jacobson, I., Bonacini, et al
ELSEVIER.2021: S736
- **Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Kwong, A., Kim, W. R., Kwo, P. Y., Wang, U., Cheng, X.
2021

- **How Clinicians May Use Tests of Hepatic Function Now and In the Future.** *Translational research : the journal of laboratory and clinical medicine*
Ghaziani, T. T., Kwo, P. Y.
2021
- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation.** *Hepatology communications*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W. R., Nguyen, M. H., Esquivel, C. O., Concepcion, et al
2021; 5 (3): 516-525
- **Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat.** *Clinical liver disease*
Dhanasekaran, R., Kwo, P. Y.
2021; 17 (3): 169–73
- **Current and future strategies for the treatment of chronic hepatitis C.** *Clinical and molecular hepatology*
Alshuwaykh, O. n., Kwo, P. Y.
2021; 27 (2): 246–56
- **Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.** *Hepatology (Baltimore, Md.)*
Singal, A. K., Kwo, P., Kwong, A., Liangpunsakul, S., Louvet, A., Mandrekar, P., McClain, C., Mellinger, J., Szabo, G., Terrault, N., Thursz, M., Winder, G. S., Kim, et al
2021
- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation** *HEPATOLOGY COMMUNICATIONS*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W., Esquivel, C. O., Concepcion, W., Melcher, et al
2020
- **Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.** *The American journal of gastroenterology*
Younossi, Z. M., Noureddin, M., Bernstein, D., Kwo, P., Russo, M., Shiffman, M. L., Younes, Z., Abdelmalek, M.
2020
- **THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY**
Alshuwaykh, O., Goel, A., Daugherty, T., Cheung, A., Kim, W., Kwong, A. J., Ahmed, A., Ghaziani, T., Torok, N. J., Nguyen, M. H., Dronamraju, D., Dhanasekaran, R., Kumari, et al
WILEY.2020: 472A–473A
- **HEPATITIS C SCREENING IN POST-BABY BOOMER GENERATION AMERICANS: ONE SIZE DOES NOT FIT ALL**
Sriponapun, P., Kim, W., Udompap, P., Mannalithara, A., Kwong, A. J., Goel, A., Kwo, P. Y.
WILEY.2020: 590A
- **FEASIBILITY AND EFFICACY OF NOREPINEPHRINE IN THE NON-ICU SETTING FOR TREATMENT OF HEPATORENAL SYNDROME**
Kwong, A. J., Cheng, X., Kwo, P. Y., Wang, U., Kim, W.
WILEY.2020: 1106
- **ANALYSIS OF LONGER-TERM SAFETY PROFILE OF THE HEPATITIS B VIRUS CORE INHIBITOR ABI-H0731 IN AN OPEN LABEL EXTENSION STUDY**
Jacobson, I. M., Ma, X., Tuan Nguyen, Schiff, E. R., Yuen, M., Hann, H. L., Sulkowski, M. S., Nahass, R. G., Ramji, A., Agarwal, K., Park, J. S., Ayoub, W. S., Gane, E. J., et al
WILEY.2020: 501A–502A
- **OUTCOMES AFTER HOSPITALIZATION WITH ACUTE DECOMPENSATION DUE TO ALCOHOL-RELATED LIVER DISEASE**
Kwong, A. J., Goel, A., Daugherty, T., Kwo, P. Y., Kim, W.
WILEY.2020: 181A–182A
- **PREDICTORS OF OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC LIVER DISEASE: US MULTI-CENTER STUDY**
Adeniji, N., Kim, D., Latt, N. L., Kumar, S., Bloom, P. P., Aby, E. S., Perumalswami, P. V., Roytman, M., Li, M., Vogel, A. S., Catana, A. M., Wegermann, K., Carr, et al

WILEY.2020: 7A

● **Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis**

John, N., Alshuwaykh, O., Goel, A., Ahmed, A., Cheung, A., Dronamraju, D., Kumari, R., Daugherty, T., Dhanasekaran, R., Kim, R. W., Nguyen, M. H., Kwo, P. Y.

LIPPINCOTT WILLIAMS & WILKINS.2020: S587–S588

● **Characterizing Ascites in Subjects With Nonhepatic Solid Tumors**

Alshuwaykh, O., Cheung, A., Goel, A., Dhanasekaran, R., Ahmed, A., Dronamraju, D., Daugherty, T., Kim, R. W., Kumari, R., Torok, N., Ghaziani, T., Kwo, P. Y.

LIPPINCOTT WILLIAMS & WILKINS.2020: S507

● **More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis.** *Clinical and molecular hepatology*

Kwo, P., Dronamraju, D.

2020

● **Viral Hepatitis Other than A, B, and C: Evaluation and Management.** *Clinics in liver disease*

Cheung, A., Kwo, P.

2020; 24 (3): 405–19

● **Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression**

Reddy, R., Curry, M., Dieterich, D., Ankoma-Sey, V., Pan, C., Hann, H., Tong, M., Kim, W., Kwo, P., Frazier, L., Cox, K., Milligan, S., Afdhal, et al

ELSEVIER.2020: S881-S882

● **Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection**

Fung, S., Sulkowski, M., Lalezari, J., Schiff, E. R., Dieterich, D., Hassanein, T., Kwo, P., Elkhashab, M., Nahass, R., Ayoub, W., Han, S., Bonacini, M., Alves, et al

ELSEVIER.2020: S51-S52

● **Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice**

Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., Hann, H., Tong, M., Kim, W., Kwo, P., Frazier, L., Cox, K., Milligan, et al

ELSEVIER.2020: S876

● **Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C)**

Goel, A., Downing, L., Dang, J., Jayasekera, C., Kwo, P.

ELSEVIER.2020: S822

● **Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US**

Sripongpun, P., Goel, A., Mannalithara, A., Kwo, P., Kim, W.

ELSEVIER.2020: S828-S829

● **Building a better mousetrap: can MELD-Na be improved?**

Kwong, A., Mannalithara, A., Kwo, P., Kim, W.

ELSEVIER.2020: S689

● **Sustained Virologic Remission in an 8-Month-Old Pediatric Patient with Carbamoyl Phosphate Synthetase I Deficiency and Hepatitis C Infection Using Direct Acting Antivirals Prior to Liver Transplant.** *Journal of pediatric gastroenterology and nutrition*

Huang, A. C., Beadles, A., Romero, D., Berquist, W., Bensen, R., Kwo, P., Mckenzie, R. B.

2020

● **Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.** *Journal of viral hepatitis*

Nangia, G., Vierling, J. M., Kwo, P., Brown, D. D., Klopfer, S. O., Robertson, M. N., Haber, B. A., Reddy, K. R.

2020

● **HCV treatment in 2020: How to translate highly effective therapies into elimination strategies.** *Hepatology forum*

Alshuwaykh, O., Kwo, P. Y.

2020; 1 (2): 72-74

- **HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL**
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, Reddy, R., Pan, C., Hann, H. W., Tong, M., Kim, W. R., Kwo, P., Frazier, L., Cox, K., Milligan, S., et al
ELSEVIER SCIENCE INC.2020: S169
- **Improving Liver Transplant (LT) Waitlist Attrition**
Concepcion, W., Ahmed, A., Tulu, Z., Hogan, L., Bonham, A., Gallo, A., Melcher, M., Kwo, P., Esquivel, C.
WILEY.2020: 284–85
- **Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post-Transplant Clinical Outcome.** *Clinical transplantation*
Adeniji, N. n., Arjunan, V. n., Prabhakar, V. n., Tulu, Z. n., Kambham, N. n., Ahmed, A. n., Kwo, P. n., Dhanasekaran, R. n.
2020: e14128
- **Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5/6: An Integrated Analysis of Phase 2/3 Studies.** *Liver international : official journal of the International Association for the Study of the Liver*
Yao, B. B., Fredrick, L. M., Schnell, G. n., Kowdley, K. V., Kwo, P. Y., Poordad, F. n., Nguyen, K. n., Lee, S. S., George, C. n., Wong, F. n., Gane, E. n., Abergel, A. n., Spearman, et al
2020
- **Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter?** *Alimentary pharmacology & therapeutics*
Kwong, A. J., Kwo, P. Y.
2020; 51 (7): 739–40
- **Novel use of endoscopic morcellator to clear large obscuring clot in patient with upper-GI bleed.** *VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy*
Gubatan, J. n., Kwo, P. n., Hwang, J. H.
2020; 5 (2): 58–60
- **Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Kim, D. n., Adeniji, N. n., Latt, N. n., Kumar, S. n., Bloom, P. P., Aby, E. S., Perumalswami, P. n., Roytman, M. n., Li, M. n., Vogel, A. S., Catana, A. M., Wegermann, K. n., Carr, et al
2020
- **DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.** *Journal of hepatology*
Verna, E. C., Morelli, G. n., Terrault, N. A., Lok, A. S., Lim, J. K., Di Bisceglie, A. M., Zeuzem, S. n., Landis, C. S., Kwo, P. n., Hassan, M. n., Manns, M. P., Vainorius, M. n., Akushevich, et al
2020
- **Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.** *Journal of clinical gastroenterology*
Saab, S. n., Bernstein, D. n., Hassanein, T. n., Kugelmas, M. n., Kwo, P. n.
2020
- **Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Adeniji, N. n., Arjunan, V. n., Prabhakar, V. n., Mannalithara, A. n., Ghaziani, T. n., Ahmed, A. n., Kwo, P. n., Nguyen, M. n., Melcher, M. L., Busuttill, R. W., Florman, S. S., Haydel, B. n., Ruiz, et al
2020
- **Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.** *Journal of hepatology*
Abdallah, M. A., Kuo, Y. F., Asrani, S. n., Wong, R. J., Ahmed, A. n., Kwo, P. n., Terrault, N. n., Kamath, P. S., Jalan, R. n., Singal, A. K.
2020
- **Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients with Chronic Hepatitis B.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Sripongpun, P. n., Kim, W. R., Mannalithara, A. n., Kwong, A. n., Daugherty, T. n., Goel, A. n., Kwo, P. Y.
2020
- **CONTINUED THERAPY WITH ABI-H0731+NRTI RESULTS IN SEQUENTIAL REDUCTION/LOSS OF HBV DNA, HBV RNA, HBeAg, HBcrAg AND HBsAg IN HBeAg POSITIVE PATIENTS**

Sulkowski, M. S., Agarwal, K., Fung, S. K., Yuen, M., Ma, X., Lalezari, J. P., Nguyen, T. T., Bae, H. S., Schiff, E. R., Hassanein, T., Hann, H. L., Elkhatab, M., Dieterich, et al
WILEY.2019: 1486A–1487A

- **DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL PRACTICE**
Curry, M. P., Bae, H. S., Dieterich, D. T., Ankoma-Sey, V., Reddy, K., Pan, C. Q., Hann, H. L., Tong, M. J., Kim, W., Kwo, P., Frazier, L., Cox, K., Milligan, et al
WILEY.2019: 308A–309A
- **Sustained Decline of Noninvasive Fibrosis Index Values in Patients With Chronic Hepatitis C (CHC) With Sustained Virologic Response (SVR) After Receiving Direct-Acting Antiviral Agents (DAAs)**
Prabhakar, V., Lutchman, G., Ahmed, A., Nguyen, M. H., Daugherty, T., Kwo, P.
LIPPINCOTT WILLIAMS & WILKINS.2019: S553–S554
- **Novel Use of EndoRotor (R) Device to Clear Large Obscuring Clot in Patient With Upper Gastrointestinal Bleed**
Gubatan, J., Kwo, P., Hwang, J.
LIPPINCOTT WILLIAMS & WILKINS.2019: S1182
- **THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT)**
Prabhakar, V., Dhanasekaran, R., Arjunan, V., Tulu, Z., Ahmed, A., Daugherty, T., Kumari, R., Patel, B., Kim, W., Goel, A., Esquivel, C. O., Concepcion, W., Melcher, et al
WILEY.2019: 691A–692A
- **IS IT GOOD IDEA TO OFFER TRANSPLANT EXCEPTION POINTS FOR SEPTUAGENARIANS WITH HEPATOCELLULAR CARCINOMA (HCC)?**
Arjunan, V., Prabhakar, V., Raghavan, S., Tulu, Z., Kambham, N., Ahmed, A., Kwo, P., Dhanasekaran, R.
WILEY.2019: 557A–558A
- **CLINICOPATHOLOGICAL FEATURES OF NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC)**
Arjunan, V., Prabhakar, V., Raghavan, S., Tulu, Z., Kambham, N., Ahmed, A., Kwo, P., Dhanasekaran, R.
WILEY.2019: 548A
- **HEP B CONSULT: A POINT-OF-CARE INTERACTIVE DECISION SUPPORT TOOL DELIVERS REAL-TIME, PERSONALIZED, GUIDELINE-BASED TEACHING AND REVEALS VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN THE MANAGEMENT OF HBV INFECTION**
Schwartz, Z., Schulz, J., King, E., Agarwal, K., Wong, G. L., Kwo, P.
WILEY.2019: 302A
- **CHANGING POPULATION OF LIVER TRANSPLANT RECIPIENTS IN THE ERA OF DIRECT ACTING ANTIVIRAL THERAPY FOR HEPATITIS C VIRUS INFECTION**
Xie, C., Abdallah, M., Wong, R. J., Kwo, P., Thuluvath, P., Asrani, S. K., Singal, A. K.
WILEY.2019: 679A
- **LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION**
Reddy, K., Curry, M. P., Bae, H. S., Dieterich, D. T., Ankoma-Sey, V., Pan, C. Q., Hann, H. L., Tong, M. J., Kim, W., Kwo, P., Frazier, L., Cox, K., Milligan, et al
WILEY.2019: 309A
- **Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014** *LIVER INTERNATIONAL*
Kim, D., Cholankeril, G., Li, A. A., Kim, W., Tighe, S. P., Hameed, B., Kwo, P. Y., Harrison, S. A., Younossi, Z. M., Ahmed, A.
2019; 39 (9): 1661–71
- **Toward Elimination of Hepatitis C Infection: How Best to Address Gaps in the Cascade of Care?** *Hepatology communications*
Prabhakar, V., Kwo, P. Y.
2019; 3 (9): 1174–76
- **A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis**
Lawitz, E., Gane, E., Ruane, P., Herring, R., Younes, Z. H., Kwo, P., Zhang, J., Jia, C., Chuang, J., McColgan, B., Chung, C., Subramanian, M., Myers, et al

E M H SWISS MEDICAL PUBLISHERS LTD.2019: 25S

- **iLFT: A big assist in the recognition of liver disease in general practice.** *Journal of hepatology*
Cheung, A. C., Kwo, P. Y.
2019
- **Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease.** *Journal of palliative medicine*
Adejumo, A. C., Kim, D., Iqbal, U., Yoo, E. R., Boursiquot, B. C., Cholankeril, G., Wong, R. J., Kwo, P. Y., Ahmed, A.
2019
- **y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection** *JOURNAL OF GASTROENTEROLOGY*
Naganuma, A., Chayama, K., Notsumata, K., Gane, E., Foster, G. R., Wyles, D., Kwo, P., Crown, E., Bhagat, A., Mensa, F. J., Otani, T., Larsen, L., Burroughs, et al
2019; 54 (8): 752–61
- **EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: AN INTEGRATED ANALYSIS OF PHASE 2 AND 3 STUDIES**
Yao, B. B., Asselah, T., Frederick, L., Schnell, G., Kowdley, K., Kwo, P. Y., Poordad, F., Kinh Nguyen, Lee, S. S.
BMJ PUBLISHING GROUP.2019: A146–A147
- **Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors** *AMERICAN JOURNAL OF TRANSPLANTATION*
Kwong, A. J., Wall, A., Melcher, M., Wang, U., Ahmed, A., Subramanian, A., Kwo, P. Y.
2019; 19 (5): 1380–87
- **CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US**
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, Reddy, R., Pan, C., Hann, H. W., Tong, M., Kim, W. R., Kwo, P., Frazier, L., Milligan, S., Radtchenko, J., et al
ELSEVIER SCIENCE INC.2019: S196
- **Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies**
Yao, B., Asselah, T., Fredrick, L., Schnell, G., Kowdley, K. V., Kwo, P., Poordad, F., Kinh Nguyen, Lee, S., Mensa, F.
ELSEVIER SCIENCE BV.2019: E248
- **Using Liver Transplant (LT) Data And Analytics to Improve Program Clinical and Financial Performance.**
Bonham, A., Tulu, Z., Concepcion, W., Gallo, A., Melcher, M., Kwo, P., Ahmed, A., Esquivel, C.
WILEY.2019: 583–84
- **A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis**
Lawitz, E., Gane, E., Ruane, P., Herring, J., Younes, Z. H., Kwo, P., Zhang, J., Jia, C., Chuang, J., Mccolgan, B., Chung, C., Subramanian, M., Myers, et al
ELSEVIER SCIENCE BV.2019: E794
- **Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice**
Curry, M., Bae, H., Dieterich, D., Ankoma-Sey, V., Reddy, R., Pan, C., Hann, H., Tong, M., Kim, W., Kwo, P., Frazier, L., Milligan, S., Spitz, et al
ELSEVIER SCIENCE BV.2019: E462
- **Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients**
Ma, X., Lalezari, J., Tuan Nguyen, Bae, H., Schiff, E. R., Fung, S., Yuen, M., Hassanein, T., Hann, H., Elkhatab, M., Dieterich, D., Sulkowski, M., Kwo, P., et al
ELSEVIER SCIENCE BV.2019: E130
- **Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.** *Journal of gastroenterology*
Naganuma, A., Chayama, K., Notsumata, K., Gane, E., Foster, G. R., Wyles, D., Kwo, P., Crown, E., Bhagat, A., Mensa, F. J., Otani, T., Larsen, L., Burroughs, et al
2019

- **Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis** *JOURNAL OF VIRAL HEPATITIS*
Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., Kwo, P. Y., Weiland, O., Villa, E., Heo, J., Gane, E., Ryder, S. D., Welzel, et al
2019; 26 (3): 337–49
- **Diagnosis and Management of Primary Biliary Cholangitis** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W., Kowdley, K. V., Jacobson, I. M.
2019; 114 (1): 48–63
- **Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.** *PloS one*
Kwo, P. Y., Puenpatom, A. n., Zhang, Z. n., Hui, S. L., Kelley, A. A., Muschi, D. n.
2019; 14 (8): e0218759
- **Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy.** *International journal of women's health*
Hezode, C., Kwo, P., Sperl, J., Hwang, P., Long, J., Talwani, R., Robertson, M. N., Haber, B. A.
2019; 11: 617–28
- **Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014.** *Liver international : official journal of the International Association for the Study of the Liver*
Kim, D. n., Cholankeril, G. n., Li, A. A., Kim, W. n., Tighe, S. P., Hameed, B. n., Kwo, P. Y., Harrison, S. A., Younossi, Z. M., Ahmed, A. n.
2019
- **Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Sripongpun, P. n., Mannalithara, A. n., Kwo, P. Y., Kim, W. R.
2019
- **The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer** *PLOS ONE*
Wong, K., Ozeki, K., Kwong, A., Patel, B. N., Kwo, P.
2018; 13 (12)
- **Diagnosis and Management of Primary Biliary Cholangitis.** *The American journal of gastroenterology*
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., Jacobson, I. M.
2018
- **Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.** *Journal of viral hepatitis*
Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., Kwo, P. Y., Weiland, O., Villa, E., Heo, J., Gane, E., Ryder, S. D., Welzel, et al
2018
- **Liver Transplantation for HCV Non-Viremic Recipients with HCV Viremic Donors.** *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*
Kwong, A. J., Wall, A., Melcher, M., Wang, U., Ahmed, A., Subramanian, A., Kwo, P. Y.
2018
- **Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection** *HEPATOLOGY*
Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., Gane, E., Kao, J., Mantry, P. S., Mutimer, D., Reddy, K., Tran, T. T., Hu, et al
2018; 68 (4): 1298–1307
- **Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice; Real-World Evidence from the Trio Network**
Curry, M. P., Bae, H., Dieterich, D. T., Ankoma-Sey, V., Reddy, K., Pan, C. Q., Hann, H. L., Tong, M. J., Kim, W., Kwo, P., Reau, N., Frazier, L., Milligan, et al
WILEY.2018: 252A
- **Treatment of Hepatitis B in the Us; Real-World Evidence from the Trio Network**
Bae, H., Curry, M. P., Dieterich, D. T., Ankoma-Sey, V., Reddy, K., Pan, C. Q., Hann, H. L., Tong, M. J., Kim, W., Kwo, P., Reau, N., Frazier, L., Milligan, et al
WILEY.2018: 264A–265A

- **PROOF OF CONCEPT STUDY OF AN APOPTOSIS-SIGNAL REGULATING KINASE (ASK1) INHIBITOR (SELONSERTIB) IN COMBINATION WITH AN ACETYL-COA CARBOXYLASE INHIBITOR (GS-0976) OR A FARNESOID X RECEPTOR (FXR) AGONIST (GS-9674) IN NASH**
Lawitz, E., Herring, R., Younes, Z. H., Gane, E., Ruane, P. J., Aguilar, R., Jia, C., Xu, R., McColgan, B., Oberle, C., Djedjos, C., Subramanian, G., McHutchison, et al
E M H SWISS MEDICAL PUBLISHERS LTD.2018: 24S
- **Proof-of-concept study of an apoptosis-signal regulating kinase inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in non-alcoholic steatohepatitis**
Gane, E., Lawitz, E., Herring, R., Younes, Z. H., Ruane, P. J., Aguilar, R., Jia, C., Xu, R., Mccolgan, B., Djedjos, S., Subramanian, M., Mchutchison, J. G., Myers, et al
WILEY.2018: 57–58
- **DAA's and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist Response** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Kwo, P. Y., Shiffman, M. L., Bernstein, D. E.
2018; 113 (8): 1251–52
- **Response to Perrella et al.** *The American journal of gastroenterology*
Kwo, P. Y., Shiffman, M. L., Bernstein, D. E.
2018
- **Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Cholankeril, G., Gonzalez, H. C., Satapathy, S. K., Gonzalez, S. A., Hu, M., Khan, M., Yoo, E. R., Li, A. A., Kim, D., Nair, S., Wong, R. J., Kwo, P. Y., Harrison, et al
2018; 16 (6): 965–+
- **Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy**
Dore, G., Hezode, C., Kwo, P., Sperl, J., Hwang, P., Long, J., Talwani, R., Robertson, M., Haber, B.
WILEY.2018: 56–57
- **Pragmatic Surgical Risk Assessment Criteria in Critically Ill Patients Prior to Liver Transplantation.**
Bonham, C., Tulu, Z., Melcher, M., Kwo, P., Concepcion, W., Ahmed, A., Esquivel, C.
WILEY.2018: 849–50
- **Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation.**
Kwong, A., Wall, A., Melcher, M., Wang, U., Ahmed, A., Khush, K., Subramanian, A., Tan, J., Kwo, P.
WILEY.2018: 464
- **Daclatasvir and Sofosbuvir Treatment of Decompensated Liver Disease or Post-Liver Transplant Hepatitis C Virus Recurrence in Patients With Advanced Liver Disease/Cirrhosis in a Real-World Cohort** *HEPATOLOGY COMMUNICATIONS*
Kwo, P., Fried, M. W., Reddy, K., Soldevila-Pico, C., Khemichian, S., Darling, J., Zamor, P. J., Napoli, A. A., Anduze-Faris, B., Brown, R. S.
2018; 2 (4): 354–63
- **Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH**
Lawitz, E., Herring, R., Younes, Z. H., Gane, E., Ruane, P., Schall, R. A., Jia, C., Xu, R., Mccolgan, B., Djedjos, S., Subramanian, M., Mchutchison, J. G., Myers, et al
ELSEVIER SCIENCE BV.2018: S57
- **Dynamic Visual Processing in Patients with Decompensated Cirrhosis**
Wong, K., Liston, D., Papademetriou, S., Yeoh, A., Goel, A., Kwo, P., Okafor, P.
ELSEVIER SCIENCE BV.2018: S726
- **Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis**
Poordad, F., Zeuzem, S., Asatryan, A., Foster, G., Gane, E., Wyles, D., Stanislas, P., Ferret, M. B., Kwo, P., Asselah, T., Kowdley, K. V., Hezode, C., Agarwal, et al
ELSEVIER SCIENCE BV.2018: S262
- **Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy**

Hezode, C., Kwo, P., Sperl, J., Dore, G., Hwang, P., Long, J., Talwani, R., Robertson, M., Haber, B.
 ELSEVIER SCIENCE BV.2018: S264–S265

- **Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
 Cholankeril, G., Gonzalez, H. C., Satapathy, S., Gonzalez, S. A., Hu, M., Khan, M. A., Yoo, E. R., Li, A. A., Kim, D., Nair, S., Wong, R. J., Kwo, P. Y., Harrison, et al
 2018
- **Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial** *HEPATOLOGY*
 Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., Maliakkal, B., Agarwal, K., Hassanein, T., Weilert, F., Lee, S. S., Kort, J., Lovell, et al
 2018; 67 (2): 514–23
- **Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection** *NEW ENGLAND JOURNAL OF MEDICINE*
 Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., Asselah, T., Bourriere, M., Ruane, P. J., Wedemeyer, H., Pol, S., Flisiak, R., Poordad, et al
 2018; 378 (4): 354–69
- **The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
 Kwo, P. Y., Shiffman, M. L., Bernstein, D. E.
 2018; 113 (1): 2–4
- **The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.** *PLoS one*
 Wong, K., Ozeki, K., Kwong, A., Patel, B. N., Kwo, P.
 2018; 13 (12): e0208233
- **Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment.** *Case reports in hepatology*
 Charville, G. W., Padda, S. K., Sibley, R. K., Puthillath, A., Kwo, P. Y.
 2018; 2018: 3413592
- **The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment** *DRUG SAFETY*
 Sinclair, S. M., Jones, J. K., Miller, R. K., Greene, M. F., Kwo, P. Y., Maddrey, W. C.
 2017; 40 (12): 1205–18
- **Drug-drug interactions in hepatitis C virus treatment: Do they really matter?** *Clinical liver disease*
 Ahmed, A., Lutchman, G. A., Kwo, P. Y.
 2017; 10 (5): 111–15
- **Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States**
 Rahim, U., Cholankeril, G., Yoo, E. R., Liu, A., Li, A. A., Kim, D., Kwo, P. Y., Ahmed, A., Goel, A.
 WILEY.2017: 708A
- **Initial Uptake and Time to Treatment of all Oral Direct Acting Antivirals for Hepatitis C**
 Kwo, P., Zhang, Z., Knapp, K., Hui, S., Kelley, A., Muschi, D., Puenpatom, A.
 NATURE PUBLISHING GROUP.2017: S502
- **Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis**
 Flamm, S. L., Wyles, D. L., Wang, S., Mutimer, D. J., Rockstroh, J. K., Horsmans, Y. J., Kwo, P. Y., Weiland, O., Villa, E., Heo, J., Gane, E. J., Ryder, S. D., Welzel, et al
 WILEY.2017: 35A–36A
- **A Prognostic Model for Liver Transplant Candidates with Hepatitis C - A Decision Aid for Antiviral Therapy**
 Lee, H., Mannalithara, A., Asrani, S. K., Biggins, S. W., Heimbach, J., Brandman, D., Abt, P. L., Kwo, P. Y., Kim, W.
 WILEY.2017: 548A–549A
- **Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts**

Wilson, E., Davitkov, P., Kwo, P. Y., Kattakuzhy, S., Qureshi, K., Sundaram, V., Naik, S., Williams, L. A., Wolf, J., Llewellyn, J., Osinusi, A. O., Brainard, D. M., Gordon, et al
WILEY.2017: 608A

- **Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.** *Hepatology (Baltimore, Md.)*
Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., Maliakkal, B., Agarwal, K., Hassanein, T., Weilert, F., Lee, S. S., Kort, J., Lovell, et al
2017
- **International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates** *TRANSPLANTATION*
Terrault, N. A., McCaughan, G. W., Curry, M. P., Gane, E., Fagiuoli, S., Fung, J. Y., Agarwal, K., Lilly, L., Strasser, S. I., Brown, K. A., gadano, a., Kwo, P. Y., Burra, et al
2017; 101 (5): 945-955
- **International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients** *TRANSPLANTATION*
Terrault, N. A., Berenguer, M., Strasser, S. I., gadano, a., Lilly, L., Samuel, D., Kwo, P. Y., Agarwal, K., Curry, M. P., Fagiuoli, S., Fung, J. Y., Gane, E., Brown, et al
2017; 101 (5): 956-967
- **Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.** *Journal of hepatology*
Kwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., Felizarta, F., Sulkowski, M. S., Gane, E., Maliakkal, B., Overcash, J. S., Gordon, S. C., Muir, et al
2017
- **International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.** *Transplantation*
Terrault, N. A., McCaughan, G. W., Curry, M. P., Gane, E., Fagiuoli, S., Fung, J., Agarwal, K., Lilly, L., Strasser, S. I., BROWN, K., Gadano, A., Kwo, P. Y., Burra, et al
2017
- **International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.** *Transplantation*
Terrault, N., Berenguer, M., Strasser, S., gadano, a., Lilly, L., Samuel, D., Kwo, P. Y., Agarwal, K., Curry, M., Fagiuoli, S., Fung, J. Y., Gane, E., Brown, et al
2017
- **Confirming What We Believed: Reducing and Eliminating Vertical Transmission of Hepatitis B.** *Gastroenterology*
Kligman, E., Kwo, P. Y.
2017
- **Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Liangpunsakul, S., Kwo, P. Y.
2017; 15 (2): 289-291
- **Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection** *GASTROENTEROLOGY*
Kwo, P., Gane, E. J., Peng, C., Pearlman, B., Vierling, J. M., Serfaty, L., Buti, M., Shafran, S., Stryszak, P., Lin, L., Gress, J., Black, S., Dutko, et al
2017; 152 (1): 164-?
- **MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection**
Reau, N., Kwo, P. Y., Rhee, S., Brown, R. S., Agarwal, K., Angus, P., Gane, E., Kao, J., Mantry, P. S., Reddy, K. R., Tran, T. T., Hu, Y. B., Gulati, et al
ELSEVIER SCIENCE BV.2017: S90–S91
- **Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study**
Vierling, J. M., Sobhonslidsuk, A., Papatheodoridis, G., Assy, N., Rosenberg, W., Guyader, D., Dev, A., Gordon, S. C., Pol, S., Luketic, V. A., Khemichian, S., Evans, B., Morgan, et al
ELSEVIER SCIENCE BV.2017: S521–S522

- **Safety and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir and +/- ribavirin in adult renal or liver transplant recipients with HCV infection (CORAL-I: cohorts 3-6)**
Agarwal, K., Brown, R. S., Dumas, E. O., McCaughan, G. W., Samuel, D., Terrault, N., Brown, K. A., Mantry, P. S., Berenguer, M., Kwo, P. Y., O'leary, J., Charafeddine, M., Pilot-Matias, et al
ELSEVIER SCIENCE BV.2017: S529–S530
- **The Liver in Oncology.** *Clinics in liver disease*
Dhanasekaran, R. n., Kwo, P. Y.
2017; 21 (4): 697–707
- **Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.** *Gastroenterology*
Kwo, P., Gane, E. J., Peng, C., Pearlman, B., Vierling, J. M., Serfaty, L., Buti, M., Shafran, S., Stryszak, P., Lin, L., Gress, J., Black, S., Dutko, et al
2017; 152 (1): 164-175 e4
- **ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.** *American journal of gastroenterology*
Kwo, P. Y., Cohen, S. M., Lim, J. K.
2017; 112 (1): 18-35
- **All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Reddy, K. R., Lim, J. K., Kuo, A., Di Bisceglie, A. M., Galati, J. S., Morelli, G., Everson, G. T., Kwo, P. Y., Brown, R. S., Sulkowski, M. S., Akushevich, L., Lok, A. S., Pockros, et al
2017; 45 (1): 115-126
- **ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Kwo, P. Y., Cohen, S. M., Lim, J. K.
2017; 112 (1): 17-36
- **High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis** *GASTROENTEROLOGY*
Gane, E., Poordad, F., Wang, S., Asatryan, A., Kwo, P. Y., Lalezari, J., Wyles, D. L., Hassanein, T., Aguilar, H., Maliakkal, B., Liu, R., Lin, C., Ng, et al
2016; 151 (4): 651-?
- **High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals**
Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., Jacobson, I. M., Tran, T., Nahass, R., Hinestrosa, F., Herring, R., Bennett, M., Llewellyn, et al
NATURE PUBLISHING GROUP.2016: S380
- **After the Direct-acting Antivirals Are Gone, There Is Still Work to Be Done in the Liver** *GASTROENTEROLOGY*
Kwo, P. Y., Lacerda, M. A.
2016; 151 (4): 582-584
- **Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study** *HEPATOLOGY*
Kwo, P., Gitlin, N., Nahass, R., Bernstein, D., Etkorn, K., Rojter, S., Schiff, E., Davis, M., Ruane, P., Younes, Z., Kalmeijer, R., Sinha, R., Peeters, et al
2016; 64 (2): 370-380
- **Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.** *Gastroenterology*
Gane, E., Kowdley, K. V., Pound, D., Stedman, C. A., Davis, M., Etkorn, K., Gordon, S. C., Bernstein, D., Everson, G., Rodriguez-Torres, M., Tsai, N., Khalid, O., Yang, et al
2016
- **Hepatic arterial buffer response: pathologic evidence in non-cirrhotic human liver with extrahepatic portal vein thrombosis** *MODERN PATHOLOGY*
Rush, N., Sun, H., Nakanishi, Y., Mneimneh, W., Kwo, P. Y., Saxena, R.
2016; 29 (5): 489-499

- **Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)** *JOURNAL OF HEPATOLOGY*
Chan, H. L., Ahn, S. H., Chang, T., Peng, C., Wong, D., Coffin, C. S., Lim, S. G., Chen, P., Janssen, H. I., Marcellin, P., Serfaty, L., Zeuzem, S., Cohen, et al
2016; 64 (5): 1011-1019
- **Risk factors for bleeding after liver biopsy** *ABDOMINAL RADIOLOGY*
Sandrasegaran, K., Thayalan, N., Thavanesan, R., Kohli, M., Berry, W., Shah, A., Kwo, P.
2016; 41 (4): 643-649
- **Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial** *GASTROINTESTINAL ENDOSCOPY*
Rex, D. K., Clodfelter, R., Rahmani, F., Fatima, H., James-Stevenson, T. N., Tang, J. C., Kim, H. N., McHenry, L., Kahi, C. J., Rogers, N. A., Helper, D. J., Sagi, S. V., Kessler, et al
2016; 83 (1): 166-171
- **HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS**
Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., Jacobson, I., Tran, T. T., Nahass, R., Hineostroza, F., Herring, R., Bennet, M., Yang, et al
ELSEVIER SCIENCE BV.2016: S139-S140
- **SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS**
Gane, E. J., Nguyen, M., Kwo, P., Kowdley, K., Reau, N., Jacobson, I., Curry, M., Pearlman, B., Khalid, O., Everson, G., Gordon, S., Poulos, J., Sheikh, et al
ELSEVIER SCIENCE BV.2016: S758-S759
- **Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis** *NEW ENGLAND JOURNAL OF MEDICINE*
Curry, M. P., O'Leary, J. G., Bzowej, N., Muir, A. J., Korenblat, K. M., Fenkel, J. M., Reddy, K. R., Lawitz, E., Flamm, S. L., Schiano, T., Teperman, L., Fontana, R., Schiff, et al
2015; 373 (27): 2618-2628
- **Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease** *GASTROENTEROLOGY*
Charlton, M., Everson, G. T., Flamm, S. L., Kumar, P., Landis, C., Brown, R. S., Fried, M. W., Terrault, N. A., O'Leary, J. G., Vargas, H. E., Kuo, A., Schiff, E., Sulkowski, et al
2015; 149 (3): 649-659
- **Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy.** *Practical radiation oncology*
Lasley, F. D., Mannina, E. M., Johnson, C. S., Perkins, S. M., Althouse, S., Maluccio, M., Kwo, P., Cárdenes, H.
2015; 5 (5): e443-9
- **Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials** *HEPATOLOGY*
Alqahtani, S. A., Afdhal, N., Zeuzem, S., Gordon, S. C., Mangia, A., Kwo, P., Fried, M., Yang, J. C., Ding, X., Pang, P. S., McHutchison, J. G., Pound, D., Reddy, et al
2015; 62 (1): 25-30
- **The Presence of Portal Vein Thrombosis Alters the Classic Enhancement Associated with Diagnosis of Hepatocellular Carcinoma** *DIGESTIVE DISEASES AND SCIENCES*
Umar, N. K., Badshah, M. B., Sandrasegaran, K., Ghabril, M., Agarwal, S., Tann, M., Lacerda, M., Kwo, P. Y.
2015; 60 (7): 2196-2200
- **Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Muir, A. J., Poordad, F., Lalezari, J., Everson, G., Dore, G. J., Herring, R., Sheikh, A., Kwo, P., Hezode, C., Pockros, P. J., Tran, A., Yozviak, J., Reau, et al
2015; 313 (17): 1736-1744
- **Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*

- Poordad, F., Sievert, W., Mollison, L., Bennett, M., Tse, E., Braeu, N., Levin, J., Sepe, T., Lee, S. S., Angus, P., Conway, B., Pol, S., Boyer, et al
2015; 313 (17): 1728-1735
- **An Interferon-free Antiviral Regimen for HCV after Liver Transplantation** *NEW ENGLAND JOURNAL OF MEDICINE*
Kwo, P. Y., Mantry, P. S., Coakley, E., Te, H. S., Vargas, H. E., Brown, R., Gordon, F., Levitsky, J., Terrault, N. A., Burton, J. R., Xie, W., Setze, C., Badri, et al
2014; 371 (25): 2375-2382
 - **Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials** *JOURNAL OF HEPATOLOGY*
Vierling, J. M., Zeuzem, S., Poordad, F., Bronowicki, J., Manns, M. P., Bacon, B. R., Esteban, R., Flamm, S. L., Kwo, P. Y., Pedicone, L. D., Deng, W., Dutko, F. J., DiNubile, et al
2014; 61 (2): 200-209
 - **The future of hepatitis C virus therapeutics.** *Gastroenterology & hepatology*
Kwo, P. Y.
2014; 10 (7): 433-435
 - **Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity** *HEPATOLOGY INTERNATIONAL*
Burman, B. E., Kwo, P. Y., Kowdley, K. V.
2014; 8 (3): 352-364
 - **Role of Cardiac Catheterization and Percutaneous Coronary Intervention in the Preoperative Assessment and Management of Patients Before Orthotopic Liver Transplantation** *LIVER TRANSPLANTATION*
Maddur, H., Bourdillon, P. D., Liangpunsakul, S., Tector, A. J., Fridell, J. A., Ghabril, M., Lacerda, M. A., Bourdillon, C., Shen, C., Kwo, P. Y.
2014; 20 (6): 664-672
 - **Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant** *CLINICAL TRANSPLANTATION*
Kwo, P. Y., Ghabril, M., Lacerda, M. A., Tector, A. J., Fridell, J. A., Vianna, R.
2014; 28 (6): 722-727
 - **Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis** *NEW ENGLAND JOURNAL OF MEDICINE*
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., Rustgi, V., Chojkier, M., Herring, et al
2014; 370 (20): 1879-1888
 - **Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection** *NEW ENGLAND JOURNAL OF MEDICINE*
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J., Agarwal, K., Buggisch, P., Foster, G. R., Braeu, N., Buti, et al
2014; 370 (20): 1889-1898
 - **Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials** *LIVER INTERNATIONAL*
Manns, M. P., McCone, J., Davis, M. N., Rossaro, L., Schiff, E., Shiffman, M. L., Bacon, B., Bourliere, M., Sulkowski, M. S., Bruno, S., Balart, L., Bronowicki, J., Kwo, et al
2014; 34 (5): 707-719
 - **Ethical Considerations Surrounding Survival Benefit-Based Liver Allocation** *LIVER TRANSPLANTATION*
Keller, E. J., Kwo, P. Y., Helft, P. R.
2014; 20 (2): 140-146
 - **Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1** *NEW ENGLAND JOURNAL OF MEDICINE*
Kowdley, K. V., Lawitz, E., Poordad, F., Cohen, D. E., Nelson, D. R., Zeuzem, S., Everson, G. T., Kwo, P., Foster, G. R., Sulkowski, M. S., Xie, W., Pilot-Matias, T., Liou, et al
2014; 370 (3): 222-232
 - **Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.** *N Engl J Med*
N, A., et al
2014; 370 (16): 1483-93.

- **Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics** *ANTIVIRAL RESEARCH*
Lawitz, E., Sulkowski, M., Jacobson, I., Kraft, W. K., Maliakkal, B., Al-Ibrahim, M., Gordon, S. C., Kwo, P., Rockstroh, J. K., Panorchan, P., Miller, M., Caro, L., Barnard, et al
2013; 99 (3): 214-220
- **De novo malignancy post-liver transplantation: a single center, population controlled study** *CLINICAL TRANSPLANTATION*
Chatrath, H., Berman, K., Vuppalanchi, R., Slaven, J., Kwo, P., Tector, A. J., Chalasani, N., Ghabril, M.
2013; 27 (4): 582-590
- **Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis** *LIVER TRANSPLANTATION*
Kwo, P. Y., Tector, A. J.
2013; 19 (7): 780-781

PRESENTATIONS

- Increased Nonlysosomal Serine Protease Activity Contributes To Bile Acid-Induced Apoptosis in Hepatocytes - GI Grand Rounds (9/21/1994)
- Helicobacter Pylori and Peptic Ulcer Disease - Medical Grand Rounds (7/17/1996)
- Morbidity and Mortality Conference: A 66 Year Old Man with Hematochezia - LaPorte Hospital (2/17/1996)
- Neuropathology Update - Department of Neurology, Indiana University School of Medicine (3/2/1996)
- Hepatitis C Epidemiology, Diagnosis, and Treatment - Henry County Hospital (4/1/1997)
- Recent Advances in Hepatitis C, Problem Solving: Hepatitis C Cases - Annual Meeting of Indiana Chapters of ACP and ASIM (11/21/1997)
- Medical and Endoscopic Approaches to Variceal Bleeding - Second Annual Venous and Hemodialysis Intervention Symposium (2/8/1998)
- Hepatitis C and Primary Care - United Samaritans Medical Center, Medical Grand Round (3/13/1998)
- Hepatic Manifestations of Inflammatory Bowel Disease - Inflammatory Bowel Disease Preceptorship Program (4/2/1998)
- Hepatitis C, What it is, What it does, and How You Treat It - Hemophilia Foundation of Greater Cincinnati, Inc., Annual Meeting (4/27/1998)
- Hepatitis C - Hemophilia Foundation of Indiana, Inc. Annual Meeting (5/2/1998)
- New Therapies for Hepatitis C - Hemophilia Foundation of Indiana, Inc (6/13/1998)
- Treatment of Hepatitis C, Treatment of Variceal Bleeding - Hepatology Update, Indiana University School of Medicine (9/18/1998)
- Hepatitis C, Epidemiology, Diagnosis and Treatment - Medical Grand Rounds, Culver Hospital (9/29/1998)
- Clinical Development Investigators Meeting: Hepatitis Treatment in Medically Complex Patients (12/1998)
- Approach to the Patient with Normal ALT - 3rd Annual Rebetron Investigators Meeting (2/25/1999)
- Medical and Endoscopic Approaches to Variceal Bleeding. - 3rd Annual Venous and Hemodialysis Intervention Symposium (2/27/1999)
- Treatment of Hepatitis C, Update in Gastroenterology - Indiana University Medical Center (4/16/1999)
- Epidemiology, Diagnosis and Treatment of Hepatitis C - Indiana State Department of Health (5/20/1999)
- Growing Evidence Supports Combination Therapy in Non-responders to Interferon - Clinician's Companion III Development Meeting (6/1999)
- Pre-and Post Liver Transplantation Treatment for Hepatitis C Patients: Non-responders to Interferon Monotherapy (7/10/1999)
- Medical Grand Rounds: Hepatitis C - Terre Haute Medical Society (10/1/1999)
- Expanding General Gastroenterology Practice: Contemporary Approaches to Treating Patients with Hepatitis C - American College of Gastroenterology (10/17/1999)
- Medical Grand Rounds: Hepatitis C - Methodist Hospital (11/18/1999)
- Special Issues in the Treatment of Hepatitis C Patients - 4th Annual Rebetron Investigators Meeting (2/11/2011)
- Medical and Endoscopic Approaches to Variceal Bleeding - 4th Annual Venous and Hemodialysis Intervention Symposium (2/26/2000)
- Hepatitis C - Medical Grand Round (3/6/2000)
- Hepatic Manifestations of Inflammatory Bowel Disease - Inflammatory Bowel Disease Preceptorship Program (4/7/2000)

- Gastroesophageal Reflux Disease - Medical Grand Rounds (6/6/2000)
- Plenary Speaker - Hepatitis C Video Conference (6/14/2000)
- Prognosis in Compensated Viral Cirrhosis - Clinician's Companion IV Development Meeting (6/2000)
- Treatment of Hepatitis C; Hepatology Update (9/22/2000)
- Treatment of Hepatitis B (9/22/2000)
- "Treatment of Hepatitis C - Gastroenterology Update 2000 for Primary Care Physician (11/15/2000)
- Hepatitis C - Medical Grand Rounds (12/5/2000)
- Hepatitis C. Diagnosis and Treatment - Internal Medicine Update: St Joseph Hospital (1/13/2001)
- Treatment of Hepatitis C in the era of Pegylated Interferon and Ribavirin - CME Conference Host (1/23/2001)
- Approach to the Patient with Normal ALT - 5th Annual Rebetrone Investigators Meeting (2/10/2001)
- Ethnospecific Aspects of Care in Patients with HCV infection - 2001 Clinician's Companion III Development Meeting (6/21/2001 - 6/24/2001)
- Treatment of Chronic HCV Infection - Indiana Hemophilia and Thrombosis Center Annual Meeting (8/25/2001)
- Treatment of Chronic Hepatitis C - Methodist Medical Group, Managed Care Conference (8/5/2001)
- Management of Side Effects in the Treatment of HCV Infection - American College of Gastroenterology (8/21/2001)
- ABC's of Hepatitis - Indiana State Department of Health Immunization Conference (10/26/2001)
- Building a Research Career with Industry - Mayo Clinic, GI Division, Research Retreat (11/16/2001)
- Hepatitis C and Liver Transplantation - Clarian Health Liver Transplant Support Group (2/20/2002)
- Lecture I: Approach to the Patient's Abnormal Liver Chemistries. Lecture II: Complications of Cirrhosis - St. Mary's Health Care Services Annual AmeriCard Update (3/7/2002)
- What the Primary Care Physician Needs to Know About Referring Patients for Orthotopic Liver Transplantation - Medical Grand Rounds, St. Mary's Health Care Service (7/17/2002)
- Update on Hepatitis C - Medical Grand Round (8/6/2002)
- ARK (Hepatitis C Support Group) - Westside Nazarene Church (9/21/2002)
- Update on Hepatitis C - Medical Grand Round (10/29/2002)
- Hepatocellular Carcinoma, the Hepatologist's Perspective - Oncology Grand Round (9/15/2006)
- New Therapies for Hepatitis C - Annual Japanese Association for the Study of Liver Disease Summit (8/23/2007 - 8/24/2007)
- Treatment of Hepatitis B that Minimizes Resistance - American College of Gastroenterology State-of-the-Art Lecture (10/16/2007)
- Hepatitis B: Dilemmas and Opportunities, "Then, What Do You Treat With?" - American College of Gastroenterology Annual Meeting (10/16/2007)
- Orthotopic Liver Transplant, Expanding the Donor Pool and Treatment Outcomes, Novel Therapies for Hepatitis C - Gastroenterology Grand Rounds (11/26/2007)
- Treatment of Hepatitis C - State-of-the-Art Canadian Digestive Disease Week, Fourth Annual Canadian Association for the Society of the Study of Liver Disease (CASL) (3/1/2008)
- NAFLD: A Worldwide Problem - APASL State of the Art Lecture (5/18/2009)
- Meeting Advancing the Border of Treatment Challenges in Hepatitis C (10/5/2009 - 10/7/2009)
- Opportunities to Reduce Morbidity and Mortality in Those Asians with Chronic Hepatitis B - Asian Pacific American Medical Student Association (10/31/2009)
- Evaluation of Abnormal Liver Chemistry - Medical Grand Rounds (10/1/2009)
- Novel Therapies for Hepatitis C - Japan Hepatitis Summit (9/26/2009)
- Treatment of Hepatitis C Non-Responders - North Shore University Hospital, Long Island Jewish Medical Center (10/3/2009)
- Novel Therapies for the Treatment of Chronic Hepatitis C - Medical Grand Rounds (12/11/2009)
- Practical Strategies for Improving Outcomes in Patients with Chronic Hepatitis C Virus Infection - Grand Rounds (1/30/2010)
- Topics in Nutritional Challenges - Methodist Hospital, Clarian Department of Nutrition (2/19/2010)

- Liver Transplantation in 2010 - Sinai Hospital, Wasserman Lectureship (3/8/2010)
- Boceprevir in the Treatment of Hepatitis C, Advantages and Disadvantages - X International Symposium On Viral Hepatitis 2010 (5/22/2010)
- Hepatitis C, Indianapolis Liver Update 2010 - American Liver Foundation and the Indiana University School of Medicine (12/3/2010)
- Management of Hepatitis C -Entering a New Era-Preparing Your Practices for New Treatments Using Response Guided Therapy and Managing Side Effects - ACG Annual meeting (10/31/2011)
- Hepatitis C Post Transplant - Grand Rounds (3/2013)
- Hepatitis C Post Transplant - Grand Rounds (5/2013)
- Hepatitis C, the Future Has Arrived - Mayo Clinic (11/2013)
- HCV: Has the Future Arrived? - The Liver Week 2014, The Korean Association for the Study of the Liver (6/13/2014)
- Interferon-based vs. Interferon-free Regimens: Do We Need Interferon Based Regimens with DAAs Before Entering the Interferon Free Era - The Liver Week 2014, The Korean Association for the Study of the Liver (6/13/2014)
- All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in Treatment-naïve Genotype 1 HCV-infected Patients - he Liver Week 2014, The Korean Association for the Study of the Liver (6/13/2014)
- All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in Treatment-experienced Genotype 1 HCV-infected Patients - The Liver Week 2014, The Korean Association for the Study of the Liver (6/13/2014)
- Hepatitis C: The Future Has Arrived (2/27/2015)
- Hepatitis B Session - APASL (3/12/2015)
- Ledipasvir Sofosbuvir is Effective as a Single Tablet Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Including Those with Traditional Negative Predictors - APASL (3/13/2015)
- The Impact of the Treatment of HCV in Developing Hepatocellular Carcinoma - APASL (3/15/2015)
- What is New: Debrief of Hepatitis - AASLD/ Chinese Society of Hepatology Joint Meeting (7/17/2015)
- Hepatitis C Management: AASLD Guideline & Application in Practice - AASLD/ Chinese Society of Hepatology Joint Meeting (7/17/2015)
- Safety and Efficacy of Oral Therapy with Grazoprevir and Elbasvir for Chronic Hepatitis C - 2nd Pan-Asian Conference on Haemoglobinopathies (9/27/2015)
- Optimizing SVR in "Difficult to Cure" Patient Populations - HCV Symposium, AASLD (11/16/2015)
- Management of Chronic Hepatitis C in 2016: Pre and Post Transplant Setting - XXVII Simposio Associazione ONLUS Roberto Farini (1/29/2016)